An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL
Recruitment status was Active, not recruiting
To analyze the change in International Prostate Symptom Score (IPSS) and serum prostate-specific antigen (PSA) level from baseline.
Benign Prostatic Hyperplasia
|Study Design:||Observational Model: Case-Only|
|Official Title:||An Observational Study of Dutasteride and Alpha-Blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL|
|Study Start Date:||December 2010|
|Estimated Study Completion Date:||December 2013|
This is a non-interventional, observational and multicenter study. When subjects will be allowed the dutasteride and α-blocker orally once daily for two years by investigator's prescription. They will be invited to this observational study. All eligible subjects can be allowed the prior alpha blockers therapy. Details of acute urinary retention (AUR) and BPH-related prostatic surgery episodes will be recorded at every visit. Subjects will return to the clinic for assessment every 3 months until week 96. The efficacy and safety of combining the 5α-reductase inhibitor (5ARI), dutasteride, and the α-blocker will be assessed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01351987
|Taipei Medical University - WanFang Hospital|
|Principal Investigator:||Liang-Ming Lee||Taipei Medical University WanFang Hospital|